Care of Transgender Persons | NEJM
Clinical Practice from The New England Journal of Medicine — Care of Transgender Persons
Related Articles
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | NEJM
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results…
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | NEJM
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy…
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat | NEJM
A series of recent actions by the Trump administration upend the country’s approach to Covid-19 vaccination and may portend a broader shift in the government’s…
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether…
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We…
Cutaneous Extramedullary Plasmacytoma after Bone Fracture | NEJM
A 69-year-old man with multiple myeloma presented with an enlarging purple skin mass on his right shoulder at the surgical site of a recent intramedullary…